



Equivalent of Form PTO/SB/08a (7-09)

JAN 1920

Substitute for form 1449/PTO

**SECOND SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 1

| | | | |
|--|---|--------------------------|----------------------|
| Substitute for form 1449/PTO | | <i>Complete if Known</i> | |
| SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | Application Number | 10/551,209 |
| | | Filing Date | September 28, 2005 |
| | | First Named Inventor | Denise Marie BAKER |
| | | Art Unit | 1644 |
| | | Examiner Name | M. DiBrino |
| Sheet | 1 | of | 1 |
| | | Attorney Docket Number | 2473.0260001/EKS/PAC |

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

1071332v1

| | | | |
|-----------------------|--------------------|--------------------|------------|
| Examiner Signature | /Marianne Dibrino/ | Date Considered | 04/06/2010 |
|-----------------------|--------------------|--------------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.D./

| | | | | | |
|--|---|----|----|---------------------------------|----------------------|
| Substitute for form 1449/PTO | | | | <i>Complete if Known</i> | |
| SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Application Number | 10/551,209 |
| | | | | Filing Date | September 28, 2005 |
| | | | | First Named Inventor | Denise Marie BAKER |
| | | | | Art Unit | 1644 |
| | | | | Examiner Name | M. DiBrino |
| Sheet | 1 | of | 15 | Attorney Docket Number | 2473.0260001/EKS/PAC |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
|--------------------|-----------------------|--|----------------|
| | NPL159 | Alexander, J., et al., "Development of High Potency Universal DR-Restricted Helper Epitopes by Modification of High Affinity DR-Blocking Peptides," <i>Immunity</i> 1:751-761, Cell Press, Massachusetts (1994) | |
| | NPL160 | Alonso, M.J., et al., "Biodegradable Microspheres as Controlled-release Tetanus Toxoid Delivery System," <i>Vaccine</i> 12:299-306, Elsevier Ltd., London (1994) | |
| | NPL161 | Alter, H.J., "Chronic Consequences of Non-A, Non-B Hepatitis," in <i>Current Perspectives in Hepatology</i> , eds., Seeff, L.B., and Lewis, J.H., pp. 83-97, Plenum Publishing Corporation, New York (1989) | |
| | NPL162 | Alter, M.J., et al., "The Natural History of Community-Acquired Hepatitis C in the United States," <i>The New England Journal of Medicine</i> 327:1899-1905, Massachusetts Medical Society, Boston (1992) | |
| | NPL163 | Altman, J.D., et al., "Formation of Functional Peptide Complexes of Class II Major Histocompatibility Complex Proteins from Subunits Produced in <i>Escherichia Coli</i> ," <i>Proc. Natl. Acad. Sci. USA</i> 90:10330-10334, National Academy of Sciences (1993) | |
| | NPL164 | Altman, J.D., et al., "Phenotypic Analysis of Antigen-Specific T Lymphocytes," <i>Science</i> 274:94-96, The American Association for the Advancement of Science, Washington DC, USA (1993) | |
| | NPL165 | Altuvia, Y., et al., "Ranking Potential Binding Peptides to MHC Molecules by a Computational Threading Approach," <i>Journal of Molecular Biology</i> 249:244-250, Academic Press, London (1995) | |
| | NPL166 | Altuvia, Y., et al., "A Structure-Based Algorithm to Predict Potential Binding Peptides to MHC Molecules with Hydrophobic Binding Pockets," <i>Human Immunology</i> 58:1-11, Elsevier Science Inc., New York, USA (1997) | |
| | NPL167 | An, L and Whitton, J.L., "A Multivalent Minigene Vaccine, Containing B-Cell, Cytotoxic T-Lymphocyte, and T _h Epitopes from Several Microbes, Includes Appropriate Responses In Vivo and Confers Protection Against More than One Pathogen," <i>Journal of Virology</i> 71:2292-2302, American Society for Microbiology, Washington DC, USA (1997) | |
| | NPL168 | Barber, L.D., et al., "Overlap in the Repertoires of Peptides Bound In Vivo by a Group of Related Class I HLA-B Allotypes," <i>Current Biology</i> 5:179-190, Current Biology Ltd., London (1995) | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.D./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|---|----|----|---------------------------------|----------------------|
| Substitute for form 1449/PTO | | | | <i>Complete if Known</i> | |
| SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Application Number | 10/551,209 |
| | | | | Filing Date | September 28, 2005 |
| | | | | First Named Inventor | Denise Marie BAKER |
| | | | | Art Unit | 1644 |
| | | | | Examiner Name | M. DiBrino |
| Sheet | 2 | of | 15 | Attorney Docket Number | 2473.0260001/EKS/PAC |

| NON PATENT LITERATURE DOCUMENTS | | | | | |
|--|-----------------------|--|--|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published | | | T ² |
| | NPL169 | Borrow, P., et al., "Antiviral Pressure Exerted by HIV-1-Specific Cytotoxic T Lymphocytes (CTLs) During Primary Infection Demonstrated by Rapid Selection of CTL Escape Virus," <i>Nature Medicine</i> 3:205-211, Nature Publishing Co., New York (1997) | | | |
| | NPL170 | Brusic, V., et al., "Prediction of MHC Class II-binding Peptides Using an Evolutionary Algorithm and Artificial Neural Network," <i>Bioinformatics</i> 14:121-130, Oxford University Press, Oxford, UK (1998) | | | |
| | NPL171 | Busch, R., et al., "Degenerate Binding of Immunogenic Peptides to HLA-DR Proteins on B Cell Surfaces," <i>International Immunology</i> 2:443-451, Oxford University Press, Oxford, UK (1990) | | | |
| | NPL172 | Buus, S., "Description and Prediction of Peptide-MHC Binding: the 'Human MHC Project,'" <i>Current Opinion in Immunology</i> 11:209-213, Current Biology Publications, London (1999) | | | |
| | NPL173 | Ceppellini, R., et al., "Binding of Labelled Influenza Matrix Peptide to HLA DR in Living B Lymphoid Cells," <i>Nature</i> 339:392-394, Macmillan Magazines Ltd., London (1989) | | | |
| | NPL174 | Cerundolo, V., et al., "The Binding Affinity and Dissociation Rates of Peptides for Class I Major Histocompatibility Complex Molecules," <i>European Journal of Immunology</i> 21:2069-2075, VCH Verlagsgesellschaft mbH, Germany (1991) | | | |
| | NPL175 | Chakrabartii, S., et al., "Expression of the HTLV-III Envelope Gene by a Recombinant Vaccinia Virus," <i>Nature</i> 320:535-537, Macmillan Journals Ltd., London (1986) | | | |
| | NPL176 | Chanda, P.K., et al., "High Level Expression of the Envelope Glycoproteins of the Human Immunodeficiency Virus Type I in Presence of Rev Gene Using Helper-Independent Adenovirus Type 7 Recombinants," <i>Virology</i> 175:535-547, Academic Press Inc., USA (1990) | | | |
| | NPL177 | Chisari, F.V., and Ferrari, C., "Hepatitis B Virus Immunopathogenesis," <i>Annual Review of Immunology</i> 13:29-60, Annual Reviews Inc., Palo Alto, California, USA (1995) | | | |
| | NPL178 | Choo, Q., et al., "Isolation of a cDNA Clone Derived from a Blood-Borne Non-A, Non-B Viral Hepatitis Genome," <i>Science</i> 244:359-362, American Association for the Advancement of Science, Washington DC, USA (1989) | | | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

All REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.D./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|---|----|----|--|--|
| Substitute for form 1449/PTO | | | | <i>Complete if Known</i> | |
| SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Application Number Filing Date First Named Inventor Art Unit Examiner Name | 10/551,209 September 28, 2005 Denise Marie BAKER 1644 M. DiBrino |
| Sheet | 3 | of | 15 | Attorney Docket Number 2473.0260001/EKS/PAC | |

| NON PATENT LITERATURE DOCUMENTS | | | | | |
|--|-----------------------|--|--|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published | | | T ² |
| | NPL179 | Christnick, E.R., <i>et al.</i> , "Peptide Binding to Class I MHC on Living Cells and Quantitation of Complexes Required for CTL Lysis," <i>Nature</i> 352:67-70, Macmillan Magazines Ltd., London (1991) | | | |
| | NPL180 | Cooney, E.L., <i>et al.</i> , "Enhanced Immunity to Human Immunodeficiency Virus (HIV) Envelope Elicited by a Combined Vaccine Regimen Consisting of Priming with a Vaccinia Recombinant Expressing HIV Envelope and Boosting with gp160 Protein," <i>Proc. Natl. Acad. Sci. USA</i> 90:1882-1886, National Academy of Sciences (1993) | | | |
| | NPL181 | Cornette, J.L., <i>et al.</i> , "Hydrophobicity Scales and Computational Techniques for Detecting Amphipathic Structures in Proteins," <i>Journal of Molecular Biology</i> 195:659-685, Academic Press Inc., London (1987) | | | |
| | NPL182 | Dartmann, K., <i>et al.</i> , "The Nucleotide and Genome Organization of Human Papilloma Virus Type II," <i>Virology</i> 151:124-130, Academic Press Inc., Florida, USA (1986) | | | |
| | NPL183 | Davis, G.L., <i>et al.</i> , "Treatment of Chronic Hepatitis C with Recombinant Interferon Alfa," <i>The New England Journal of Medicine</i> 321:1501-1506, Massachusetts Medical Society, Boston, USA(1989) | | | |
| | NPL184 | Deamer, D. and Bangham, A.D., "Large Volume Liposomes by an Ether Vaporization Method," <i>Biochimica et Biophysica Acta</i> 443:629-634, Elsevier Scientific Publishing Company, Amsterdam (1976) | | | |
| | NPL185 | Dienstag, J.L., "Non-A, Non-B Hepatitis. I. Recognition, Epidemiology, and Clinical Features," <i>Gastroenterology</i> 85:439-462, American Gastroenterological Association, New York, USA (1983) | | | |
| | NPL186 | Doolan, D.L., <i>et al.</i> , "Cytotoxic T Lymphocyte (CTL) Low-Responsiveness to the <i>Plasmodium Falciparum</i> Circumsporozoite Protein in Naturally-Exposed Endemic Populations: Analysis of Human CTL Response to Most Known Variants," <i>International Immunology</i> 5:37-46, Oxford University Press, London (1993) | | | |
| | NPL187 | del Guercio, M., <i>et al.</i> , "Binding of a Peptide Antigen to Multiple HLA Alleles Allows Definition of an A2-Like Supertype," <i>The Journal of Immunology</i> 154:685-693, The American Association of Immunologists, Maryland, USA (1995) | | | |
| | NPL188 | DiBrino, M., <i>et al.</i> , "Endogenous Peptide with Distinct Amino Acid Anchor Residue Motifs Bind to HLA-A1 and HLA-B8," <i>The Journal of Immunology</i> 152:620-631, The American Association of Immunologists, Maryland, USA (1994) | | | |

| | | |
|--------------------|--|-----------------|
| Examiner Signature | | Date Considered |
|--------------------|--|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

All references considered except those listed on pages 1 through 15. /M.D./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|---|----|----|--------------------------|----------------------|
| Substitute for form 1449/PTO | | | | Complete if Known | |
| SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Application Number | 10/551,209 |
| | | | | Filing Date | September 28, 2005 |
| | | | | First Named Inventor | Denise Marie BAKER |
| | | | | Art Unit | 1644 |
| | | | | Examiner Name | M. DiBrino |
| Sheet | 4 | of | 15 | Attorney Docket Number | 2473.0260001/EKS/PAC |

| NON PATENT LITERATURE DOCUMENTS | | | | |
|--|-----------------------|---|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published | | T ² |
| | NPL189 | Devereux, J., et al., "A Comprehensive Set of Sequence Analysis Programs for the VAX," <i>Nucleic Acids Research</i> 12:387-395, IRL Press Limited, Oxford, England (1984) | | |
| | NPL190 | Debs, R.J., et al., "Regulation of Gene Expression <i>In Vivo</i> by Liposome-Mediated Delivery of a Purified Transcription Factor," <i>The Journal of Biological Chemistry</i> 265:10189-10192, The American Society for Biochemistry and Molecular Biology, Inc., Baltimore, USA (1990) | | |
| | NPL191 | Dunbar, P.R., et al., "Direct Isolation, Phenotyping ad Cloning of Low-Frequency Antigen-Specific Cytotoxic T Lymphocytes from Peripheral Blood," <i>Current Biology</i> 8:413-416, Current Biology Ltd., London (1998) | | |
| | NPL192 | Egan, J.E., et al., "Efficacy of Murine Malaria Sporozoite Vaccines: Implications for Human Vaccine Development," <i>Science</i> 236:453-456, The American Association for the Advancement of Science, Washington DC, USA (1987) | | |
| | NPL193 | Eldridge, J.H., et al., "New Advances in Vaccine Delivery Systems," <i>Seminars in Hematology</i> 30:16-25, W.B. Saunders Company, Philadelphia, USA (1993) | | |
| | NPL194 | Eldridge, J.H., et al., "Biodegradable Microspheres as a Vaccine Delivery System," <i>Molecular Immunology</i> 28:287-294, Pergamon Press plc., Oxford, UK (1991) | | |
| | NPL195 | Fauchere, J. and Pliska, V., "Hydrophobic Parameters Π of Amino-Acid Side Chains from the Partitioning of N-Acetyl-Amino-Acid Amides," <i>European Journal of Medicinal Chemistry</i> 18:369-375, S.E.C.T., Paris (1983) | | |
| | NPL196 | Felgner, P.L., et al., "Lipofection: A Highly Efficient, Lipid-Mediated DNA-Transfection Procedure," <i>Proc. Natl. Acad. Sci. USA</i> 84:7413-7417, National Academy of Sciences (1987) | | |
| | NPL197 | Robinson, W.S., "Hepadnaviridae and Their Replication," in <i>Virolog, Volume 2</i> , Chapter 26, eds., Fields, B.N., et al., pp. 2137-2169, Raven Press Ltd., New York, USA (1990) | | |
| | NPL198 | Fraley, R.T., et al., "Entrapment of a Bacterial Plasmid in Phospholipid Vesicles: Potential for Gene Transfer," <i>Proc. Natl. Acad. Sci. USA</i> 76:3348-3352, National Academy of Sciences (1979) | | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

All REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.D./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|---|----|----|--------------------------|----------------------|
| Substitute for form 1449/PTO | | | | <i>Complete if Known</i> | |
| SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Application Number | 10/551,209 |
| | | | | Filing Date | September 28, 2005 |
| | | | | First Named Inventor | Denise Marie BAKER |
| | | | | Art Unit | 1644 |
| | | | | Examiner Name | M. DiBrino |
| Sheet | 5 | of | 15 | Attorney Docket Number | 2473.0260001/EKS/PAC |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published | T ² |
| | NPL199 | Fraley, R., et al., "Introduction of Liposome-Encapsulated SV40 DNA into Cells," <i>The Journal of Biological Chemistry</i> 255:10431-10435, The American Society of Biological Chemists, Inc., Baltimore, USA (1980) | |
| | NPL200 | Franco, A., et al., "Pathogenetic Effector Function of CD4-Positive T Helper 1 Cells in Hepatitis B Virus Transgenic Mice," <i>The Journal of Immunology</i> 159:2001-2008, The American Association of Immunologists, Maryland, USA (1997) | |
| | NPL201 | Franke, E.D, et al., "Pan DR Binding Sequence Provides T-cell Help for Induction of Protective Antibodies Against <i>Plasmodium Yoelii</i> Sporozoites," <i>Vaccine</i> 17:1201-1205, Elsevier Science Ltd., Oxford, UK (1999) | |
| | NPL202 | Gilles, P.N., et al., "Tumor Necrosis Factor Alpha Negatively Regulates Hepatitis B Virus Gene Expression in Transgenic Mice," <i>Journal of Virology</i> 66:3955-3960, American Society for Microbiology, Washington DC, USA (1992) | |
| | NPL203 | Graham, B.S., et al., "Augmentation of Human Immunodeficiency Virus Type 1 Neutralizing Antibody by Priming with gp160 Recombinant Vaccinia and Boosting with rgp160 in Vaccinia-Naive Adults," <i>The Journal of Infectious Disease</i> 167:533-537, The University of Chicago Press, Chicago, USA (1993) | |
| | NPL204 | Guidotti, L.G., et al., "Interleukin-2 and Alpha/Beta Interferon Down-Regulate Hepatitis B Virus Gene Expression In Vivo by Tumor Necrosis Factory-Dependent and Independent Pathways," <i>Journal of Virology</i> 68:1265-1270, American Society for Microbiology, Washington DC, USA (1994) | |
| | NPL205 | Guidotti, L.G., et al., "High-Level Hepatitis B Virus Replication in Transgenic Mice," <i>Journal of Virology</i> 69:6158-6169, American Society for Microbiology, Washington DC, USA (1995) | |
| | NPL206 | Guidotti, L.G., et al., "Cytotoxic T Lymphocytes Inhibit Hepatitis B Virus Gene Expression by a Noncytolytic Mechanism in Transgenic Mice," <i>Proc. Natl. Acad. Sci. USA</i> 91:3764-3768, National Academy of (1994) | |
| | NPL207 | Gulukota, K., et al., "Two Complementary Methods for Predicting Peptides Binding Major Histocompatibility Complex Molecules," <i>Journal of Molecular Biology</i> 267:1258-1267, Academic Press, London (1997) | |
| | NPL208 | Haas, G., et al., "Dynamics of Viral Variants in HIV-1 Nef and Specific Cytotoxic T Lymphocytes In Vivo," <i>The Journal of Immunology</i> 157:4212-4221, The American Association of Immunologists, Maryland, USA (1996) | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

All REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.D./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|---|----|----|--------------------------|----------------------|
| Substitute for form 1449/PTO | | | | Complete if Known | |
| SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Application Number | 10/551,209 |
| | | | | Filing Date | September 28, 2005 |
| | | | | First Named Inventor | Denise Marie BAKER |
| | | | | Art Unit | 1644 |
| | | | | Examiner Name | M. DiBrino |
| Sheet | 6 | of | 15 | Attorney Docket Number | 2473.0260001/EKS/PAC |

| NON PATENT LITERATURE DOCUMENTS | | | | |
|--|-----------------------|---|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published | | T ² |
| | NPL209 | Hammer, J., et al., "Precise Prediction of Major Histocompatibility Complex Class II-Peptide Interaction Based on Peptide Side Chain Scanning," <i>The Journal of Experimental Medicine</i> 180:2353-2358, The Rockefeller University Press, New York, USA (1994) | | |
| | NPL210 | Handsfield, H.H., "Clinical Presentation and Natural Course of Anogenital Warts," <i>The American Journal of Medicine</i> 102:16-20, Excerpta Medica Inc., New York, USA (1997) | | |
| | NPL211 | Hanke, T., et al., "DNA Multi-CTL Epitope Vaccine for HIV and <i>Plasmodium Falciparum</i> : Immunogenicity in Mice," <i>Vaccine</i> 16:426-435, Elsevier Science Ltd., Oxford, UK (1998) | | |
| | NPL212 | Hill, A.V.S., et al., "Molecular Analysis of the Association of HLA-B53 and Resistance to Severe Malaria," <i>Nature</i> 360:434-439, Macmillan Magazine Ltd., London (1992) | | |
| | NPL213 | Hill, A.V.S., et al., "Common West African HLA Antigens are Associated with Protection from Severe Malaria," <i>Nature</i> 352:595-600, Macmillan Magazine Ltd., London (1991) | | |
| | NPL214 | Hill, C.M., et al., "Exploration of Requirements for Peptide Binding to HLA DRB1*0101 and DRB1*0401," <i>The Journal of Immunology</i> 152:2890-2898, The American Association of Immunologists, Maryland, USA (1994) | | |
| | NPL215 | Hoffman, S.L., et al., "Sporozoite Vaccine Induces Genetically Restricted T Cell Elimination of Malaria from Hepatocytes," <i>Science</i> 244:1078-1081, American Association for the Advancement of Science, Washington DC, USA (1989) | | |
| | NPL216 | Hofmann, K.J., et al., "Sequence Determination of Human Papillomavirus Type 6a and Assembly of Virus-like Particles in <i>Saccharomyces Cerevisiae</i> ," <i>Virology</i> 209:506-518, Academic Press Inc., Orlando, USA (1995) | | |
| | NPL217 | Hoofnagle, J.H., "Chronic Hepatitis B," <i>The New England Journal of Medicine</i> 323:337-339, Massachusetts Medical Society, Boston, USA (1990) | | |
| | NPL218 | Hu, S., et al., "Neutralizing Antibodies Against HIV-1 BRU and SF2 Isolates Generated in Mice Immunized with Recombinant Vaccinia Virus Expressing HIV-1 (BRU) Envelope Glycoproteins and Boosted with Homologous gp160," <i>Aids Research and Human Retroviruses</i> 7:615-620, Mary Ann Liebert, Inc., New York, USA (1991) | | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

All REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.D./

| | | | | | |
|--|---|----|----|--------------------------|----------------------|
| Substitute for form 1449/PTO | | | | Complete if Known | |
| SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Application Number | 10/551,209 |
| Sheet | 7 | of | 15 | Filing Date | September 28, 2005 |
| | | | | First Named Inventor | Denise Marie BAKER |
| | | | | Art Unit | 1644 |
| | | | | Examiner Name | M. DiBrino |
| | | | | Attorney Docket Number | 2473.0260001/EKS/PAC |

| NON PATENT LITERATURE DOCUMENTS | | | | | |
|---------------------------------|-----------------------|--|--|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published | | | T ² |
| | NPL219 | Jamieson, B.D., <i>et al.</i> , "Effective Clearance of a Persistent Viral Infection Requires Cooperation Between Virus-Specific Lyt2+ T Cells and Nonspecific Bone Marrow-Derived Cells," <i>Journal of Virology</i> 61:3930-3937, American Society for Microbiology, Washington DC, USA (1987) | | | |
| | NPL220 | Kast, W.M., <i>et al.</i> , "Role of HLA-A Motifs in Identification of Potential CTL Epitopes in Human Papillomavirus Type 16 E6 and E7 Proteins," <i>The Journal of Immunology</i> 152:3904-3912, The American Association of Immunologists, Maryland, USA (1994) | | | |
| | NPL221 | Kawashima, I., <i>et al.</i> , "The Multi-Epitope Approach for Immunotherapy for Cancer: Identification of Several CTL Epitopes from Various Tumor-Associated Antigens Expressed on Solid Epithelial Tumors," <i>Human Immunology</i> 59:1-14, Elsevier Science Inc., New York, USA (1998) | | | |
| | NPL222 | Khilko, S.N., <i>et al.</i> , "Direct Detection of Major Histocompatibility Complex Class I Binding to Antigenic Peptides Using Surface Plasmon Resonance," <i>The Journal of Biological Chemistry</i> 268:15425-15434, The American Society for Biochemistry and Molecular Biology, Baltimore, USA (1993) | | | |
| | NPL223 | Kiency, M.D., <i>et al.</i> , "Aids Virus Env Protein Expressed from a Recombinant Vaccinia Virus," <i>Biotechnology</i> 4:790-795, Nature Publishing Company, New York, USA (1986) | | | |
| | NPL224 | Koenig, S., <i>et al.</i> , "Transfer of HIV-1-specific Cytotoxic T Lymphocytes to an AIDS Patient Leads to Selection for Mutant HIV Variants and Subsequent Disease Progression," <i>Nature Medicine</i> 1:330-336, Nature Publishing Company, New York, USA (1995) | | | |
| | NPL225 | Kofler, N., <i>et al.</i> , "Preparation and Characterization of Poly-(D,L-Lactide-Co-Glycolide) and Poly-(L-Lactic Acid) Microsphere with Entrapped Pneumotropic Bacterial Antigen," <i>Journal of Immunological Methods</i> 192:25-35, Elsevier Science B.V., Amsterdam, Netherlands (1996) | | | |
| | NPL226 | Kondo, A., <i>et al.</i> , "Prominent Roles of Secondary Anchor Residues in Peptide Binding to HLA-A24 Human Class I Molecules," <i>The Journal of Immunology</i> 155:4307-4312, The American Association of Immunologists, Maryland, USA (1995) | | | |
| | NPL227 | Kondo, A., <i>et al.</i> , "Two Distinct HLA-A *0101-Specific Submotifs Illustrate Alternative Peptide Binding Modes," <i>Immunogenetics</i> 45:249-258, Springer-Verlag, Berlin, Germany (1997) | | | |
| | NPL228 | Kubo, R.T., <i>et al.</i> , "Definition of Specific Peptide Motifs for Four Major HLA-A Alleles," <i>The Journal of Immunology</i> 154:3913-3924, The American Association of Immunologists, Maryland, USA (1994) | | | |
| Examiner Signature | | Date Considered | | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.D./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|---|----|----|--------------------------|----------------------|
| Substitute for form 1449/PTO | | | | Complete if Known | |
| SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Application Number | 10/551,209 |
| | | | | Filing Date | September 28, 2005 |
| | | | | First Named Inventor | Denise Marie BAKER |
| | | | | Art Unit | 1644 |
| | | | | Examiner Name | M. DiBrino |
| Sheet | 8 | of | 15 | Attorney Docket Number | 2473.0260001/EKS/PAC |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published | T ² |
|--------------------|-----------------------|---|----------------|
| | NPL229 | Kuo, G., <i>et al.</i> , "An Assay for Circulating Antibodies to a Major Etiologic Virus of Human Non-A, Non-B Hepatitis," <i>Science</i> 244:362-364, American Association for the Advancement of Science, Washington DC, USA (1989) | |
| | NPL230 | Kyte, J. and Doolittle, R.F., "A Simple Method for Displaying the Hydropathic Character of a Protein," <i>Journal of Molecular Biology</i> 157:105-132, Academic Press Inc., London (1982) | |
| | NPL231 | Lalvani, A., <i>et al.</i> , "Rapid Effector Function in CD8 ⁺ Memory T Cells," <i>Journal of Experimental Medicine</i> 186:859-865, The Rockefeller University Press, New York, USA (1997) | |
| | NPL232 | Lane, H.C., <i>et al.</i> , "Qualitative Analysis of Immune Function in Patients with the Acquired Immunodeficiency Syndrome," <i>The New England Journal of Medicine</i> 313:79-84, The Massachusetts Medical Society, Massachusetts USA (1985) | |
| | NPL233 | Livingston, B.D., <i>et al.</i> , "Optimization of Epitope Processing Enhances Immunogenicity of Multiepitope DNA Vaccines," <i>Vaccine</i> 19:4652-4660, Elsevier Science Ltd., New York, USA (2001) | |
| | NPL234 | Ljunggren, H., <i>et al.</i> , "Empty MHC Class I Molecules Come Out in the Cold," <i>Nature</i> 346:476-480, Macmillan Magazines Ltd., London (1990) | |
| | NPL235 | Lukacher, A.E., <i>et al.</i> , "In Vivo Effector Function of Influenza Virus-Specific Cytotoxic T Lymphocyte Clones is Highly Specific," <i>The Journal of Experimental Medicine</i> 160:814-826, The Rockefeller University Press, New York, USA (1984) | |
| | NPL236 | Lukashov, V.V. and Goudsmit, J., "HIV Heterogeneity and Disease Progression in AIDS: A Model of Continuous Virus Adaption," <i>Aids</i> 12:S43-S52, Lippincott-Raven Publishers, London (1998) | |
| | NPL237 | Malik, A., <i>et al.</i> , "Human Cytotoxic T Lymphocytes Against the <i>Plasmodium Falciparum</i> Circumsporozoite Protein," <i>Proc. Natl. Acad. Sci. USA</i> 88:3300-3304, National Academy of Sciences (1991) | |
| | NPL238 | Malone, R.W., <i>et al.</i> , "Cationic Liposome-Mediated RNA Transfection," <i>Proc. Natl. Acad. Sci. USA</i> 86:6077-6081, National Academy of Sciences (1989) | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.D./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|---|----|----|---------------------------------|----------------------|
| Substitute for form 1449/PTO | | | | <i>Complete if Known</i> | |
| SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Application Number | 10/551,209 |
| | | | | Filing Date | September 28, 2005 |
| | | | | First Named Inventor | Denise Marie BAKER |
| | | | | Art Unit | 1644 |
| | | | | Examiner Name | M. DiBrino |
| Sheet | 9 | of | 15 | Attorney Docket Number | 2473.0260001/EKS/PAC |

| NON PATENT LITERATURE DOCUMENTS | | | | |
|--|-----------------------|---|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published | | T ² |
| | NPL239 | Mannino, R.I. and Gould-Fogerite, S., "Liposome Mediated Gene Transfer," <i>BioTechniques</i> 6:682-690, Eaton Publishing Company, Massachusetts, USA (1988) | | |
| | NPL240 | Marshall, K.W., <i>et al.</i> , "Role of the Polymorphic Residues in HLA-DR Molecules in Allele-Specific Binding of Peptide Ligands," <i>The Journal of Immunology</i> 152:4946-4957, The American Association of Immunologists, Maryland, USA (1994) | | |
| | NPL241 | Matteucci, M.D. and Caruthers, M.H., "Synthesis of Deoxyoligonucleotides on a Polymer Support," <i>Journal of the American Chemical Society</i> 103:3185-3191, American Chemical Society, Washington DC, USA (1981) | | |
| | NPL242 | McMichael, A.J., <i>et al.</i> , "Cytotoxic T-cell Immunity to Influenza," <i>The New England Journal of Medicine</i> 309:13-17, Massachusetts Medical Society, Boston, Massachusetts, USA (1983) | | |
| | NPL243 | McCutchan, T.F. and Waters, A.P., "Mutations with Multiple Independent Origins in Surface Antigens Mark the Targets of Biological Selective Pressure," <i>Immunology Letters</i> 25:23-26, Elsevier Science Publishers BV, Amsterdam, Netherlands (1990) | | |
| | NPL244 | Meister, G.E., <i>et al.</i> , "Two Novel T cell Epitope Prediction Algorithms Based on MHC-binding Motifs; Comparison of Predicted and Published Epitopes from <i>Mycobacterium Tuberculosis</i> and HIV Protein Sequences," <i>Vaccine</i> 13:581-591, Elsevier Science Ltd., Oxford, UK (1995) | | |
| | NPL245 | Milik, M., <i>et al.</i> , "Application of an Artificial Neural Network Binding to Predict Specific Class I MHC Binding Peptide Sequences," <i>Nature Biotechnology</i> 16:753-756, Nature America Inc., New York, USA (1998) | | |
| | NPL246 | Miller, L.H., <i>et al.</i> , "Research Toward Malaria Vaccines," <i>Science</i> 234:1349-1356, American Association for the Advancement of Science, Washington DC, USA (1986) | | |
| | NPL247 | Moreno, A., <i>et al.</i> , "Cytotoxic CD4 ⁺ T cells from a Sporozoite-Immunized Volunteer Recognize the <i>Plasmodium Falciparum</i> CS Protein," <i>International Immunology</i> 3:997-1003, Oxford University Press, Oxford, UK (1991) | | |
| | NPL248 | Nayersina, R., <i>et al.</i> , "HLA A2 Restricted Cytotoxic T Lymphocyte Responses to Multiple Hepatitis B Surface Antigen Epitopes During Hepatitis B Virus Infection," <i>The Journal of Immunology</i> 150:4659-4671, The American Association of Immunologists, Maryland, USA (1993) | | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.D./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|----|----|----|--------------------------|----------------------|
| Substitute for form 1449/PTO | | | | Complete if Known | |
| SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Application Number | 10/551,209 |
| Sheet | 10 | of | 15 | Filing Date | September 28, 2005 |
| | | | | First Named Inventor | Denise Marie BAKER |
| | | | | Art Unit | 1644 |
| | | | | Examiner Name | M. DiBrino |
| | | | | Attorney Docket Number | 2473.0260001/EKS/PAC |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published | T ² |
|--------------------|-----------------------|---|----------------|
| | NPL249 | Ogg, G.S., et al., "Quantitation of HIV-1-Specific Cytotoxic T Lymphocytes and Plasma Load of Viral RNA," <i>Science</i> 279:2103-2106, American Association for the Advancement of Science, Washington DC, USA (1998) | |
| | NPL250 | Oldstone, M.B.A., et al., "Cytoimmunotherapy for Persistent Virus Infection Reveals a Unique Clearance Pattern from the Central Nervous System," <i>Nature</i> 321:239-243, Macmillan Journals Limited, London (1986) | |
| | NPL251 | Ostro, M.J., et al., "Incorporation of High Molecular Weight RNA into Large Artificial Lipid Vesicles," <i>Biochemical and Biophysical Research Communications</i> 76:836-842, Academic Press Inc., New York, USA (1977) | |
| | NPL252 | Panina-Bordignon, P., et al., "Universally Immunogenic T Cell Epitopes: Promiscuous Binding to Human MHC Class II and Promiscuous Recognition by T Cells," <i>European Journal of Immunology</i> 19:2237-2242, Wiley-VCH Verlag GmbH & Co., Weinheim (1989) | |
| | NPL253 | Pantaleo, G., et al., "Major Expansion of CD8 ⁺ T cells with a Predominant V β usage During the Primary Immune Response to HIV," <i>Nature</i> 370:463-467, Macmillan Magazines Ltd., London (1994) | |
| | NPL254 | Papahadjopoulos, D., et al., "Cochleate Lipid Cylinders: Formation by Fusion of Unilamellar Lipid Vesicles," <i>Biochimica et Biophysica Acta</i> 394:483-491, Elsevier Scientific Publishing Company, Amsterdam, Netherlands (1975) | |
| | NPL255 | Parker, K.C., et al., "Scheme for Ranking Potential HLA-A2 Binding Peptides Based on Independent Binding of Individual Peptide Side-Chains," <i>The Journal of Immunology</i> 152:163-175, The American Association of Immunologists, Maryland, USA (1994) | |
| | NPL256 | Penna, A., et al., "Cytotoxic T Lymphocytes Recognize an HLA-A2-Restricted Epitope Within the Hepatitis B Virus Nucleocapsid Antigen," <i>Journal of Experimental Medicine</i> 174:1565-1570, The Rockefeller University Press, New York, USA (1991) | |
| | NPL257 | Pialoux, G., et al., "A Prime-Boost Approach to HIV Preventive Vaccine Using a Recombinant Canarypox Virus Expressing Glycoprotein 160 (MN) Followed by a Recombinant Glycoprotein 160 (MN/LAI)," <i>Aids Research and Human Retroviruses</i> 11:373-381, Mary Ann Liebert Inc., New York, USA (1995) | |
| | NPL258 | Pontén, J. and Guo, Z., "Precancer of the Human Cervix," <i>Cancer Surveys</i> 32:201-229, Cold Spring Harbor Laboratory Press, New York, USA (1998) | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

All REFERENCES CONSIDERED FOR THIS APPLICATION ARE LINED THROUGH. /M.D./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|----|----|----|--------------------------|----------------------|
| Substitute for form 1449/PTO | | | | Complete if Known | |
| SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Application Number | 10/551,209 |
| | | | | Filing Date | September 28, 2005 |
| | | | | First Named Inventor | Denise Marie BAKER |
| | | | | Art Unit | 1644 |
| | | | | Examiner Name | M. DiBrino |
| Sheet | 11 | of | 15 | Attorney Docket Number | 2473.0260001/EKS/PAC |

| NON PATENT LITERATURE DOCUMENTS | | | | |
|--|-----------------------|--|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published | | T ² |
| | NPL259 | Price, D.A., <i>et al.</i> , "Positive Selection of HIV-1 Cytotoxic T Lymphocyte Escape Variants During Primary Infection," <i>Proc. Natl. Acad. Sci. USA</i> 94:1890-1895, National Academy of Sciences (1997) | | |
| | NPL260 | Quinnan, G.V., <i>et al.</i> , "Cytotoxic T Cells in Cytomegalovirus Infection: HLA-Restricted T-Lymphocyte and Non-T-Lymphocyte Cytotoxic Responses Correlate with Recovery from Cytomegalovirus Infection in Bone-Marrow-Transplant Recipients," <i>The New England Journal of Medicine</i> 307:6-13, Massachusetts Medical Society, Boston, Massachusetts, USA (1982) | | |
| | NPL261 | Reay, P.A., <i>et al.</i> , "pH Dependence and Exchange of High and Low Responder Peptides Binding to a Class II MHC Molecule," <i>The Embo Journal</i> 11:2829-2839, Oxford University Press, Oxford, UK (1992) | | |
| | NPL262 | Reddehase, M.J., <i>et al.</i> , "Interstitial Murine Cytomegalovirus Pneumonia After Irradiation: Characterization of Cells That Limit Viral Replication During Established Infection of the Lungs," <i>Journal of Virology</i> 55:264-273, American Society for Microbiology, Washington DC, USA (1985) | | |
| | NPL263 | Reichard, O., <i>et al.</i> , "Randomised, Double-Blind, Placebo-Controlled Trial of Interferon α -2b with and without Ribavirin for Chronic Hepatitis C," <i>The Lancet</i> 351:83-87, The Lancet Ltd., New York, USA (1998) | | |
| | NPL264 | Rénia, L., <i>et al.</i> , "In Vitro Activity of CD4 ⁺ and CD8 ⁺ T Lymphocytes from Mice Immunized with a Synthetic Malaria Peptide," <i>Immunology</i> 88:7963-7967, Proceedings of the National Academy of Science of the United States of America, Washington DC, USA (1991) | | |
| | NPL265 | Ressing, M.E., <i>et al.</i> , "Detection of T Helper Responses, But Not of Human Papillomavirus-Specific Cytotoxic T Lymphocyte Responses, After Peptide Vaccination of Patients with Cervical Carcinoma," <i>Journal of Immunotherapy</i> 23:255-266, Lippincott Williams & Williams Inc., Maryland, USA (2000) | | |
| | NPL266 | Romero, P., <i>et al.</i> , "Cloned Cytotoxic T Cells Recognize an Epitope in the Circumsporozoite Protein and Protect Against Malaria," <i>Nature</i> 341:323-326, Macmillan Magazines Ltd., London (1989) | | |
| | NPL267 | Rosenberg, E.S., <i>et al.</i> , "Vigorous HIV-1-Specific CD4 ⁺ T Cell Responses Associated with Control of Viremia," <i>Science</i> 278:1447-1450, American Association for the Advancement of Sciences, Washington DC, USA (1997) | | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

All references considered in completing this form are listed on page 1 of this application.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|----|----|----|--------------------------|----------------------|
| Substitute for form 1449/PTO | | | | Complete if Known | |
| SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Application Number | 10/551,209 |
| Sheet | 12 | of | 15 | Filing Date | September 28, 2005 |
| | | | | First Named Inventor | Denise Marie BAKER |
| | | | | Art Unit | 1644 |
| | | | | Examiner Name | M. DiBrino |
| | | | | Attorney Docket Number | 2473.0260001/EKS/PAC |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published | T ² |
|--------------------|-----------------------|--|----------------|
| | NPL268 | Rowen, D. and Lacey, C., "Toward a Human Papillomavirus Vaccine," <i>Dermatologic Clinics</i> 16:835-838, W.B. Saunders Company, Philadelphia, Pennsylvania, USA (1998) | |
| | NPL269 | Schaefer-Ridder, M., et al., "Liposomes as Gene Carriers: Efficient Transformation of Mouse L Cells by Thymidine Kinase Gene," <i>Science</i> 215:166-168, American Association for the Advancement of Sciences, Washington DC, USA (1982) | |
| | NPL270 | Schmitz, J.E., et al., "Control of Viremia in Simian Immunodeficiency Virus Infection by CD8 ⁺ Lymphocytes," <i>Science</i> 283:857-860, American Association for the Advancement of Sciences, Washington DC, USA (1999) | |
| | NPL271 | Sercarz, E.E., et al., "Dominance and Crypticity of T Cell Antigenic Determinants," <i>Annual Reviews of Immunology</i> 11:729-766, Annual Reviews Inc., Palo Alto, California, USA (1993) | |
| | NPL272 | Sethi, K.K., et al., "Protection of Mice from fatal Herpes Simplex Virus Type 1 Infection by Adoptive Transfer of Cloned Virus-Specific and H-2-Restricted Cytotoxic T Lymphocytes," <i>The Journal of General Virology</i> 64:443-447, Society of General Microbiology, UK (1983) | |
| | NPL273 | Sette, A., et al., "Peptide Binding to the Most Frequent HLA-A Class I Alleles Measured by Quantitative Molecular Binding Assays," <i>Molecular Immunology</i> 31:813-822, Elsevier Science Ltd., Oxford, UK (1994) | |
| | NPL274 | Sidney, J., et al., "Practical Biochemical and Evolutionary Implications of the Discovery of HLA Class I Supermotifs," <i>Immunology Today</i> 17:261-266, Elsevier Science Ltd., Oxford, UK (1996) | |
| | NPL275 | Sidney, J., et al., "Definition of an HLA-A3-Like Supermotif Demonstrates the Overlapping Peptide-Binding Repertoires of Common HLA Molecules," <i>Human Immunology</i> 45:79-93, Elsevier Science Inc., New York, USA (1996) | |
| | NPL276 | Sidney, J., et al., "Measurement of MHC/Peptide Interactions by Gel Filtration," in <i>Current Protocols in Immunology</i> , pp. 18.3.1-18.3.19, John Wiley & Sons, Inc. (1998) | |
| | NPL277 | Southwood, S., et al., "Several Common HLA-DR Types Share Largely Overlapping Peptide Binding Repertoires," <i>The Journal of Immunology</i> 160:3363-3373, The American Association of Immunologists, Maryland, USA (1998) | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

All REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.D./

| | | | | | |
|--|----|----|----|--------------------------|--------------------|
| Substitute for form 1449/PTO | | | | Complete if Known | |
| SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Application Number | 10/551,209 |
| | | | | Filing Date | September 28, 2005 |
| | | | | First Named Inventor | Denise Marie BAKER |
| | | | | Art Unit | 1644 |
| | | | | Examiner Name | M. DiBrino |
| Sheet | 13 | of | 15 | Attorney Docket Number | |
| 2473.0260001/EKS/PAC | | | | | |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published | T ² |
|--------------------|-----------------------|--|----------------|
| | NPL278 | Stover, C.K., <i>et al.</i> , "New Use of BCG for Recombinant Vaccines," <i>Nature</i> 351:456-460, Macmillan Magazines Ltd., London (1991) | |
| | NPL279 | Sturniolo, T., <i>et al.</i> , "Generation of Tissue-Specific and Promiscuous HLA Ligand DatabaseS Using DNA Microarrays and Virtual HLA Class II Matrices," <i>Nature Biotechnology</i> 17:555-561, Nature America Inc., New York, USA (1999) | |
| | NPL280 | Straubinger, R.M. and Papahadjopoulos, D., "Liposomes as Carriers for Intracellular Delivery of Nucleic Acids," <i>Methods in Enzymology</i> 101:512-539, Academic Press Inc., New York, USA (1983) | |
| | NPL281 | Pfister, K., <i>et al.</i> , "Syncatalytic conformational changes in aspartate aminotransferase determined by hydrogen-deuterium exchange," <i>Proc. Natl. Acad. Sci. USA</i> 75:145-148, National Academy of Sciences (1978) | |
| | NPL282 | Takahashi, H., <i>et al.</i> , "Induction of CD8 ⁺ Cytotoxic T Cells by Immunization with Purified HIV-1 Envelope Protein in ISCOMs," <i>Nature</i> 344:873-875, Macmillan Magazines Ltd., London (1990) | |
| | NPL283 | Tam, J.P., "Recent Advances in Multiple Antigen Peptides," <i>Journal of Immunological Methods</i> 196:17-32, Elsevier Science B.V., Amsterdam, Netherlands (1996) | |
| | NPL284 | Thomson, S.A., <i>et al.</i> , "Recombinant Polyepitope Vaccines for the Discovery of Multiple CD8 Cytotoxic T Cell Epitopes," <i>The Journal of Immunology</i> 157:822-826, The American Association of Immunologists, Maryland, USA (1996) | |
| | NPL285 | Tigges, M.A., <i>et al.</i> , "Human CD8 ⁺ Herpes Simplex Virus-Specific Cytotoxic T-Lymphocyte Clones Recognize Diverse Virion Protein Antigens," <i>Journal of Virology</i> 66:1622-1634, American Society for Microbiology, Washington DC, USA (1992) | |
| | NPL286 | Top, F.H., <i>et al.</i> , "Immunization with Live Types 7 and 4 Adenovirus Vaccines. I. Safety, Infectivity, Antigenicity, and Potency of Adenovirus Type 7 Vaccine in Humans," <i>The Journal of Infectious Diseases</i> 124:148-154, The University of Chicago Press, Chicago, USA (1971) | |
| | NPL287 | Townsend, A., <i>et al.</i> , "Assembly of MHC Class I Molecules Analyzed In Vitro," <i>Cell</i> 62:285-295, Cell Press, Cambridge, Massachusetts, USA (1990) | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

All references considered except those listed on page 195 (1-800-767-3799) and selected on 2.

| | | | | | |
|--|----|----|----|--------------------------|----------------------|
| Substitute for form 1449/PTO | | | | Complete if Known | |
| SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Application Number | 10/551,209 |
| | | | | Filing Date | September 28, 2005 |
| | | | | First Named Inventor | Denise Marie BAKER |
| | | | | Art Unit | 1644 |
| | | | | Examiner Name | M. DiBrino |
| Sheet | 14 | of | 15 | Attorney Docket Number | 2473.0260001/EKS/PAC |

| NON PATENT LITERATURE DOCUMENTS | | | | |
|--|-----------------------|---|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published | | T ² |
| | NPL288 | Tsubota, H., et al., "A Cytotoxic T Lymphocyte Inhibits Acquired Immunodeficiency Syndrome Virus Replication in Peripheral Blood Lymphocytes," <i>Journal of Experimental Medicine</i> 169:1421-1434, The Rockefeller University Press, New York, USA (1989) | | |
| | NPL289 | Vitiello, A., et al., "Analysis of the HLA-Restricted Influenza-Specific Cytotoxic T Lymphocyte Response in Transgenic Mice Carrying a Chimeric Human-Mouse Class I Major Histocompatibility Complex," <i>Journal of Experimental Medicines</i> 173:1007-1015, The Rockefeller University Press, New York, USA (1991) | | |
| | NPL290 | Vitiello, A., et al., "Development of a Lipopeptide-Based Therapeutic Vaccine to Treat Chronic HBV Infection," <i>The Journal of Clinical Investigation</i> 95:341-349, The Rockefeller University Press, New York, USA (1995) | | |
| | NPL291 | Verhoef, J.C., et al., "Des-enkephalin- γ -endorphin (DE γ E): Biotransformation in Rat, Dog and Human Plasma," <i>European Journal of Drug Metabolism and Pharmacokinetics</i> 11:291-302, Medicine ET Hygiene, Geneva, Switzerland (1986) ABSTRACT ONLY | | |
| | NPL292 | Walker, B.D., et al., "Long-term Culture and Fine Specificity of Human Cytotoxic T-Lymphocyte Clones Reactive with Human Immunodeficiency Virus Type 1," <i>Proc. Natl. Acad. Sci. USA</i> 86:9514-9518, National Academy of Sciences (1989) | | |
| | NPL293 | Watari, E., et al., "A Synthetic Peptide Induces Long-Term Protection from Lethal Infection with Herpes Simplex Virus 2," <i>Journal of Experimental Medicines</i> 165:459-470, The Rockefeller University Press, New York, USA (1987) | | |
| | NPL294 | Whitton, J.L., et al., "A 'String-of-Beads' Vaccine, Comprising Linked Minigenes, Confers Protection from Lethal-Dose Virus Challenge," <i>Journal of Virology</i> 67:348-352, American Society for Microbiology, Washington DC, USA (1993) | | |
| | NPL295 | Wilson, T., et al., "The Introduction of Poliovirus RNA into Cells via Lipid Vesicles (Liposomes)," <i>Cell</i> 17:77-84, The MIT Press, Cambridge, Massachusetts, USA (1979) | | |
| | NPL296 | Wolff, J.A., et al., "Direct Gene Transfer into Mouse Muscle In Vivo," <i>Science</i> 247:1465-1468, American Association for the Advancement of Science, Washington DC, USA (1990) | | |
| | NPL297 | Yap, K.L. and Ada, G.L., "Transfer of Specific Cytotoxic T Lymphocytes Protects Mice Inoculated with Influenza Virus," <i>Nature</i> 273:238-239, Macmillan Journals Ltd., London (1978) | | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.D./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|----|----|----|--------------------------|----------------------|
| Substitute for form 1449/PTO | | | | <i>Complete if Known</i> | |
| SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Application Number | 10/551,209 |
| | | | | Filing Date | September 28, 2005 |
| | | | | First Named Inventor | Denise Marie BAKER |
| | | | | Art Unit | 1644 |
| | | | | Examiner Name | M. DiBrino |
| Sheet | 15 | of | 15 | Attorney Docket Number | 2473.0260001/EKS/PAC |

NON-PATENT LITERATURE DOCUMENTS

1071913v1

| | | | |
|--------------------|--------------------|-----------------|------------|
| Examiner Signature | /Marianne Dibrino/ | Date Considered | 04/06/2010 |
|--------------------|--------------------|-----------------|------------|

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9191 (1-800-786-9191) and select option 2.